Linagliptin Tablets

Linagliptin Tablets

(1 customer review)

$2.00

High-purity Linagliptin 5mg tablets, 7count bottle packaging by Yangtze River Pharmaceutical Group – Shanghai Henley Pharma. Ideal for DPP4 inhibitor research into Type2 diabetes mechanisms, incretin pathways, and metabolic regulation.
For laboratory research only – Not for human consumption or therapeutic use.

EMI starting from $0.00/month - View Plans
Compare

Description

Linagliptin Tablets Description

Product name: Linagliptin tablets
Packing specification: 5mg*7 tablets  Product dosage form: tablets  Packaging unit: bottle/box
Approval number: National Medicine Standard H20213378  Drug standard code: 86900841000279
Manufacturer: Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
Product barcode: 6931640900068

What is Linagliptin?

Linagliptin is a potent oral DPP4 (dipeptidyl peptidase4) inhibitor, used clinically to regulate blood sugar in Type2 Diabetes Mellitus (T2DM) by enhancing levels of active incretins zh.wikipedia.org+2zh.wikipedia.org+2bydrug.pharmcube.com+2pharm.ncmi.cn+12zh.wikipedia.org+12zh.wikipedia.org+12. Its therapeutic advantages include once daily dosing, low hypoglycemia risk, and no need for dosage adjustment in renal impairment due to biliary elimination.

This domestic product, marketed as HuYou or RuLing, is produced by Yangtze River Pharmaceutical Group’s Shanghai Henley Pharma, under NMPA approval number H20213378 with product code 86900841000279 and barcode 6931640900068.


 Product Specifications

AttributeDetails
Product NameLinagliptin Tablets (HuYou/RuLing)
Strength5mg per tablet
Quantity7 tablets per bottle
Dosage FormFilm-coated oral tablets
Approval No. (NMPA)H20213378
Pharmaceutical Product Code86900841000279
ManufacturerShanghai Henley Pharma (Yangtze River Pharmaceutical Group)
Barcode6931640900068
Shelf Life24 months
Storage ConditionsStore in cool, dry place below 30°C
Intended UseLaboratory research or analytical use only

 Mechanism of Action & Key Benefits

  • Selective DPP4 Inhibition: Increases endogenous GLP-1 and GIP, promoting insulin secretion and suppressing glucagon in a glucose-dependent way.

  • Pharmacokinetics: High oral bioavailability (~30%), strong plasma protein binding (75–99%), and long half-life enable once-daily dosing.

  • Renal Safety: Cleared mainly via bile; no dose adjustment needed in renal impairment.

  • Clinical Tolerability: Minimal hypoglycemia when used alone; mild adverse events may include headache or upper respiratory infections.


 Why Choose HuYou/RuLing Linagliptin?

  • Reputable Manufacturer: Produced by Yangtze River Pharmaceutical Group

  • Approved & Traceable: NMPA-approved with full batch traceability

  • Lab-ready Packaging: 7-tablet bottles ideal for study protocols

  • Research-grade Quality: Consistent formulation and documentation for pharmacological studies


 Related Research Substances

  • Sitagliptin Phosphate Tablets (100mg) – Jianovi

  • Vildagliptin Tablets (Weitangning 50mg)

  • Empagliflozin 10mg Tablets (SGLT2 Inhibitor)


 Summary

HuYou/RuLing Linagliptin 5mg Tablets provide a high-quality research-grade DPP4 inhibitor option with robust production credentials, stable packaging, and full regulatory traceability. Ideal for labs exploring metabolic and endocrine research.

Reminder: For laboratory research or analytical use only — not for human consumption or therapy.

Additional information

Weight1.1 kg
Dimensions18 × 16 × 22 cm

1 review for Linagliptin Tablets

  1. kristin

    Waiting for the package, thank you

Add a review

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare